

NIH Public Access

Author Manuscript

Curr Opin Microbiol. Author manuscript; available in PMC 2010 April 1.

Published in final edited form as:

Curr Opin Microbiol. 2009 April ; 12(2): 129–137. doi:10.1016/j.mib.2009.01.009.

Allostery in the LacI/GalR Family: Variations on a Theme

Liskin Swint-Kruse1 and **Kathleen S. Matthews**2

1 *Department of Biochemistry and Molecular Biology, MS 3030, 3901 Rainbow Blvd., The University of Kansas Medical Center, Kansas City, KS 66160, lswint-kruse@kumc.edu*

2 *Department of Biochemistry and Cell Biology, Rice University, Houston, TX 77005, ksm@rice.edu*

Summary

The lactose repressor protein (LacI) was among the very first genetic regulatory proteins discovered, and more than 1000 members of the bacterial LacI/GalR family are now identified. LacI has been the prototype for understanding how transcription is controlled using small metabolites to modulate protein association with specific DNA sites. This understanding has been greatly expanded by the study of other LacI/GalR homologues. A general picture emerges in which the conserved fold provides a scaffold for multiple types of interactions —including oligomerization, small molecule binding, and protein•protein binding — that in turn influence target DNA binding and thereby regulate mRNA production. Although many different functions have evolved from this basic scaffold, each homologue retains functional flexibility: For the same protein, different small molecules can have disparate impact on DNA binding and hence transcriptional outcome. In turn, binding to alternative DNA sequences may impact the degree of allosteric response. Thus, this family exhibits a symphony of variations by which transcriptional control is achieved.

Overview of the LacI/GalR family

In virtually all bacteria, LacI/GalR family members regulate transcription for a wide range of processes. First catalogued in 1992 by Weickert and Adhya [1], sequences of >1000 characterized and hypothetical homologues are now known (2008 BLAST search of Swiss-Prot). These proteins have not been found in archaebacteria or eukaryotes, although proteins with homologous domains are ubiquitous.

The LacI/GalR family can be divided into >33 paralogue groups that appear to derive from an ancestral gene. As many as 22 paralogues co-exist in a single species. Many members coordinate available nutrients with expression of catabolic genes [1], but some regulate processes as diverse as nucleotide biosynthesis and toxin expression (*e.g.* [2,3]). Two members are "master" regulators: homologues CcpA and CRA control expression of enzymes that determine carbon flow in Gram-negative and Gram-positive bacteria, respectively. If these key proteins are disabled, virulence is altered in several pathogens (*e.g.* [4,5•,6•,7]).

The common function of the LacI/GalR proteins, which features allosteric regulation of DNA binding to modulate transcription, is shown in Figure 1. Each homologue has evolved a unique variation: In addition to binding specific "operator" DNA sequences, each protein exhibits specificity for distinct effector ligands. Although most members repress transcription, some

Corresponding Author: Swint-Kruse, Liskin (E-mail: lswint-kruse@kumc.edu).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

act as both repressors and activators (*e.g.* CcpA, as reviewed in [8•]). Some homologues control one operon (*e.g.,* LacI), whereas others coordinate a set of related operons — for example, CRA controls >10 operons and PurR regulates at least 19 [9–12]). Binding the effector ligand may either decrease (induction) or increase DNA-binding affinity (co-repression), thereby altering transcription levels of downstream genes (Figure 1). As might be anticipated in a regulatory loop, effector molecules are frequently metabolically related to the regulated operon (*e.g.* [1,3,9,13,14]). In addition to or instead of small molecules, some family members bind other proteins [1,15–17].

The common monomeric structure of the LacI/GalR proteins comprises both DNA-binding and regulatory domains (Figure 2). Homodimer formation is required for high-affinity binding to operator DNA, which is usually some variation on an inverted repeat sequence (Figure 2, [1]). The two functional domains are linked by \sim 18 amino acids that mediate key interactions (see below). In the LacI/GalR family, the regulatory domains have two essential roles: (i) They receive and transmit the "input" signal from binding the effector molecule, and (ii) they mediate homodimer formation $[1,8,8,18,20]$.

Functional and allosteric variation within the LacI/GalR family

Paradigm of an inducible repressor — LacI with allolactose or IPTG

E. coli lactose repressor protein (LacI) represses the *lac* operon until it binds the physiological inducer allolactose or the gratuitous inducer IPTG (reviewed in [13,21]). The LacI dimer can effect repression and induction of the *lac* operon through binding a single high affinity operator [22,23]. In addition, wild-type LacI contains a sequence of \sim 20 amino acids at the C-terminus of the regulatory domain that promotes tetramer formation, allowing stronger repression through DNA-looping with two operator sequences (reviewed in [13]) (Figure 3). These loops have been visualized directly in single molecule experiments [24•]. At low *in vivo* inducer concentrations, one dimer within the tetramer appears to stochastically dissociate from the primary operator, leading to small bursts of gene expression [25••]. High inducer concentrations lead to LacI dissociation from both operators, increasing the duration of large bursts of gene expression [25••].

Induced LacI remains capable of binding DNA, but the affinity for the operator site is reduced ≥3 orders of magnitude, allowing excess genomic, nonspecific DNA to compete for the repressor protein. Indeed, LacI seldom dissociates from DNA *in vivo* [26]. The number of inducers that elicit induction is unknown: Thermodynamic evidence is consistent with 2 inducers/dimer [27], but others argue that one is sufficient [28]. Perhaps complexes with 0, 1, and 2 inducers bound/dimer result in distinct states with different DNA-binding properties. Gratuitous anti-inducer ligands are known that enhance LacI affinity for operator DNA, whereas "neutral" ligands bind the same effector site but elicit no change in DNA-binding affinity [27,29]

Despite extensive efforts, no high resolution structure shows a complete picture for even a single functional state of LacI (*e.g.* [20,30–33]). Nonetheless, these structures have been invaluable for successive analyses of allostery: Comparison of the LacI·O^{sym}DNA·anti-inducer and LacI·inducer structures led to the hypothesis that inducer binding shifts the N-subdomains of the regulatory domain [20,32]. These changes would ultimately impact the spacing of the N-terminal DNA-binding domains, misaligning the sites and lowering affinity. Motions between these two regulatory domain conformations were simulated with targeted molecular dynamics [34]. The predicted structural intermediates are in good agreement with existing experimental data and provide the basis for ongoing studies of LacI allostery (*e.g.*, [27,35]).

The newest X-ray structures of LacI bound to either anti-inducer or neutral ligands show very few changes in the regulatory domain compared to the inducer-bound regulatory domain structure [36•]. Thus, these structures — *including* the LacI•IPTG structure — might represent "off-pathway" conformations. True allosteric changes might be seen only in the DNA-bound ternary complexes. To that end, small-angle X-ray scattering was carried out with full-length tetrameric and dimeric LacI bound to DNA and to DNA/IPTG [37]. Only subtle conformational changes occur within the dimer•operator complex upon IPTG binding. Notably, the linker region that is extended in apo-LacI is compact in the both LacI•DNA and the induced LacI•DNA•IPTG complex. In tetrameric LacI, inducer binding led to a change in the dimer•dimer disposition, reflecting the inherent flexibility of the tetrameric arrangement.

Paradigm of a repressible system — PurR with guanine or hypoxanthine

In *E. coli*, the purine repressor protein (PurR) regulates 19 operons that control purine and pyrimidine metabolic pathways (*e.g.* [11,12]). The physiological allosteric response of PurR is opposite to that of LacI — high affinity operator binding requires the presence of co-repressor ligand [3,38,39] (Figure 1B). Co-repressors are guanine or hypoxanthine [3]. When DNAbinding affinity is measured in the presence and absence of co-repressor, the allosteric response of PurR is about 2 orders of magnitude [39], significantly smaller than LacI induction, but near that observed for anti-inducers on LacI [40•]. As with LacI, the stoichiometry of PurR:corepressor required to elicit the allosteric effect is unknown.

PurR crystallizes more readily than most other family members, and a number of structures are available for wild-type and mutant homodimers bound to DNA and a variety of corepressors (*e.g.* [41–45]). As with LacI, structures are not known for all possible functional states. Comparing structures of the apo-regulatory domain and corepressed full-length PurR, Brennan and colleagues hypothesized that large subdomain domain motions separate the DNAbinding domains too far to bind the operator half-sites [42]. The Mowbray lab [46] showed that effector binding to PurR exhibits a larger reorientation of the regulatory subdomains than does LacI. However, small-angle X-ray scattering results with a chimera comprising the LacI DNA-binding domain and the PurR regulatory domain show much smaller changes than LacI [47••]. This outcome may be an effect of either chimera formation or truncation of the PurR DNA-binding domain in the apo-PurR structure.

Paradigm of a homologue with a protein effector — CcpA

In Gram-positive bacteria, carbon catabolite protein A (CcpA) is a central regulator of carbon metabolism, controlling hundreds of genes; this homologue can function either as a repressor or an activator (reviewed in [8•,48]). Several structures of CcpA have been solved (*e.g.* [8•, 49,50]. Unlike LacI and PurR, the primary allosteric effectors of CcpA are the proteins HPr or Crh [51]. These cofactor proteins are phosphorylated at Ser46 under particular metabolic conditions. In turn, one phosphorylated cofactor binds to each monomer within a CcpA dimer, facilitating a structural change to a "closed" form and enhancing DNA binding [51] (see Figure 1B). Interestingly, binding to different cofactor proteins can affect regulation of different operons (reviewed in [8•]). The HPr-Ser46-P/Crh-Ser46-P binding site is not the same as for the small molecule effector, but lies near residues on the three strands that link the N-and Csubdomains (Figure 2, yellow region). Upon phosphoprotein binding, the conformational change seen in the CcpA regulatory domain is similar to that seen when LacI and PurR bind small effector ligands. CcpA can also bind either glucose-6-phosphate or fructose-1,6 bisphosphate in the canonical effector binding site, which enhances the cofactor function of HPr-Ser46-P but not Crh-Ser46-P (see [8•]). Interactions with HPr-Ser46-P are also observed for the *B. subtilis* homologue RbsR [52].

A distinctive paradigm — CytR

The *E. coli* cytidine repressor protein (CytR) regulates at least nine transcriptional units encoding genes involved in purine and pyrimidine biosynthesis and utilization (reviewed in [53]). CytR binds to *cytO* DNA as a homodimer; DNA-binding is cooperative in the presence of two flanking catabolite repressor proteins (CRP) (Figure 4). Notably, the spacing of *cytO* half-sites is varied and can be much wider than for the other LacI/GalR proteins [54,55]. CytR binding to its small molecule effector (cytidine) has *no* effect on intrinsic DNA binding affinity (*e.g.* [56,57••]). Instead, the cytidine-induced conformational change disallows simultaneous CytR contacts with CRP and *cytO*. As a result (i) cooperative DNA binding of CytR and CRP is diminished, allowing RNA polymerase to compete for *cytO*, and (ii) direct interactions between CRP and RNA polymerase are altered [56,57••,58].

Some of the differences in CytR function may arise from differences in the sequence linking the two functional domains (see below). No high resolution structure has been obtained, but biophysical data suggest that CytR can adopt multiple conformations in the apo-state that are constrained differently when bound to operators with distinct half-site spacings [57••]. Unlike many members of the LacI/GalR family, altered CytR•CRP interactions provide a "rheostatic" rather than "on/off" switching mechanism.

Emerging structure/function relationships in the LacI/GalR family

The regulatory domain — allostery and adaptability

The regulatory domain contains the effector and cognate protein binding sites, making this region the basic element for allostery (Figure 2). Structural changes of this domain are currently illuminated by comparison of the apo- and ligand-bound structures. LacI, PurR, and CcpA appear to have a common cleft closure, in which the N-subdomain moves and the C-subdomain remains fixed [32,42,46,50]. Changes in the regulatory domain appear to dictate the direction of allosteric response for the intact protein, as indicated by studies with chimeric repressors: When the LacI DNA-binding domain and linker are fused to the PurR regulatory domain, the chimera is co-repressed by hypoxanthine [47••], whereas when fused to the GalR regulatory domain, the chimera is induced by galactose [59•]. In LacI and GalR, several mutants that cannot respond to effector are found in the regulatory domain, in either the effector binding pocket or in regions that are crucial for allostery [60,61].

Despite its dominant role, the regulatory domain can be adapted for various functions. In addition to accommodating diverse specificities for different effectors, the regulatory domain can be either induced or co-repressed. Indeed, these alternate phenomena can occur on the *same* regulatory domain. As mentioned previously, LacI binds inducers, anti-inducers, and neutral ligands. Moreover, isothermal titration calorimetry experiments showed that ONPG, a neutral ligand for tetrameric LacI, behaved as an anti-inducer for dimeric LacI [40•]. The *E. coli* homologue GalR also has inducer (galactose and fucose) and anti-inducer (paradoxically, IPTG) ligands [62]. Although we presented PurR co-repression as "opposite" to LacI induction, a better comparison might well be the LacI•DNA•anti-inducer relationship.

Based on these observations, we propose that *all* LacI/GalR regulatory domains have potential for multiple allosteric modes. For example, a gratuitous inducer might be identified for PurR. Further, mutations that arise in evolution or are designed in the laboratory might influence the allosteric effect of ligand. Such latent allosteric potential in an ancestral regulatory domain would enable an inducible regulator to evolve the co-repression required to shutdown biosynthetic pathways (and vice versa).

The linker sequence — allosteric propagation

The 18 amino acids that join the DNA-binding domain to the regulatory domain are involved in many interfaces. These are best understood by subdividing the linker into an unstructured N-linker, a central hinge helix, and an unstructured C-linker (Figure 2). One face of the hinge helix directly contacts DNA; another face forms an interface between the two helices of a dimer; and other helix residues interact with the regulatory domain. In addition, both the Nand C-linkers interact with the regulatory domain. From the available structures, hypotheses have been formed about how structural changes are propagated to and through the respective linkers (see above). However, the only structural information available on the true allosteric complexes is low resolution from small angle X-ray scattering [37,47••]. These data show that the LacI linker remains compact in the DNA complexes of either full-length LacI or an engineered chimera comprising LacI and PurR ("LLhP").

Even though linker conformational changes may be small, mutagenesis illuminates several positions important to allostery. Formation of a disulfide bond between the LacI linkers abolished allostery for some operators, whereas inserted glycines diminished the allosteric response [63,64]. Some amino acid substitutions of the LacI C-linker position 61 abolish inducibility [60]. Other substitutions at the same residue in LLhP dramatically enhanced the magnitude of the allosteric response to co-repressor [47••]. Mutagenesis of a second chimera (comprising the LacI DNA-binding domain and the GalR regulatory domain) suggests that at least four additional linker positions may participate in allostery [59•]. Because many of these substituted positions are not conserved among family members, the effects of mutagenesis might mirror the evolution of allosteric differences between family members.

Many family members posses a conserved linker motif: Y/FxPxxxAxxL/M. A key feature is the alternative L/M side chain, which inserts into the minor groove in the center of the DNA operator [20,42,50]. A few family members lack features of the motif and/or have multiple P or G residues that are anticipated to disrupt the hinge helix. In the bacterial phylum *Firmicutes*, homologues that lack the linker motif also have a distinct operator motif [65]. Thus, the larger LacI/GalR family can be divided into two subfamilies [59•,65], which appear to have evolved different mechanisms by which the linkers bind DNA and convey allostery. For example, *E. coli* CytR lacks the L/M, has a P and a G in the "helical" region, and *cytO* is similar to the operator subfamily identified in *Firmicutes*. The linker of CytR appears to adopt multiple conformations, allowing this repressor to recognize variable spacing and rotations in the *cytO* half-sites (Figure 4) [57 $\cdot\cdot\cdot$].

DNA as an allosteric effector of LacI/GalR proteins

Thermodynamically, allostery occurs when binding to ligand A differs in the absence and presence of ligand B. To preserve a complete thermodynamic cycle, the complement must also occur. Since effector binding to LacI/GalR proteins alters DNA binding affinity, DNA binding by the LacI/GalR proteins must alter effector binding, a feature that has been directly measured (*e.g.*, [39]). Given this behavior, each specific operator sequence might exhibit a different allosteric response to small molecule effectors. This relationship has been confirmed for variants of LacI [63,64] and chimera LLhP [47••], and conceivably could contribute to the operator-specific responses seen with variants of CcpA [66•]. Many LacI/GalR proteins are known to regulate multiple operons, and an alternative allosteric response to various DNA sequences would allow their differential, but simultaneous, regulation.

Concluding remarks

The ubiquity of LacI/GalR regulatory proteins in prokaryotes testifies to the robust nature of this mechanism for conserving the energy required for mRNA and protein production [67•].

Their conserved structure has potential to be regulated by small molecules, by other proteins, or their combination. The protein structure is adaptable, demonstrating both induction and corepression within the same molecule. The structure can effect on/off switching — with $>1,000$ fold change in transcription — or can rheostatically modulate gene expression between ~ 10 and 100-fold. As we understand the intricacies of the LacI/GalR proteins, and the ways in which they can be varied, we gain the capacity to introduce "designed" regulatory systems into the cellular milieu.

Acknowledgments

We are grateful for the support of the National Institutes of Health (GM079423 and P20 RR17708 for LSK, GM22441 for KSM) and the Robert A. Welch Foundation (C-576 for KSM).

References and recommended reading

Papers of particular interest, published within the period of the review have been highlighted as:

- of special interest
- •• of outstanding interest
- 1. Weickert MJ, Adhya S. A family of bacterial regulators homologous to Gal and Lac repressors. J Biol Chem 1992;267:15869–15874. [PubMed: 1639817]
- 2. Colmer JA, Hamood AN. Characterization of *ptxS*, a *Pseudomonas aeruginosa* gene which interferes with the effect of the exotoxin A positive regulatory gene, *ptxR*. Mol Gen Genet 1998;258:250–259. [PubMed: 9645431]
- 3. Meng LM, Nygaard P. Identification of hypoxanthine and guanine as the co-repressors for the purine regulon genes of *Escherichia coli*. Mol Microbiol 1990;4:2187–2192. [PubMed: 2089227]
- 4. Seidl K, Stucki M, Ruegg M, Goerke C, Wolz C, Harris L, Berger-Bächi B, Bischoff M. *Staphylococcus aureus* CcpA affects virulence determinant production and antibiotic resistance. Antimicrob Agents Chemother 2006;50:1183–1194. [PubMed: 16569828]
- 5• . Shelburne SA III, Keith D, Horstmann N, Sumby P, Davenport MT, Graviss EA, Brennan RG, Musser JM. A direct link between carbohydrate utilization and virulence in the major human pathogen group A *Streptococcus*. Proc Natl Acad Sci USA 2008;105:1698–1703. [PubMed: 18230719]In group A *Streptococcus*, transcription of several virulence factors is related to carbohydrate utilization. Bacterial variants with a deleted CcpA gene show decreased virulence in a mouse model of invasive infection and changed expression of virulence genes on a nutrient-limited growth media. Further, purified CcpA bound directly to the promoter region of the virulence gene for steptolysin S
- 6•. Kinkel TL, McIver KS. CcpA-mediated repression of streptolysin S expression and virulence. Infect Immun 2008;76:3451–3463. [PubMed: 18490461]A CcpA deletion mutant of a group A *Steptococcus* strain shows increased virulence in a mouse model. See Shelburne *et al.* [5] which reported diminished virulence in a very similar strain. The apparent paradox between these two studies remains unresolved, but both studies show a definitive link between CcpA function and virulence. This manuscript provides citations for studies of other pathogenic bacteria in which virulence has been linked to CcpA function
- 7. Allen JH, Utley M, van Den Bosch H, Nuijten P, Witvliet M, McCormick BA, Krogfelt KA, Licht TR, Brown D, Mauel M, et al. A functional *cra* gene is required for *Salmonella enterica* serovar typhimurium virulence in BALB/c mice. Infect Immun 2000;68:3772–3775. [PubMed: 10816546]
- 8•. Schumacher MA, Seidel G, Hillen W, Brennan RG. Structural mechanism for the fine tuning of CcpA function by the small molecule effectors glucose 6-phosphate and fructose 1,6-bisphosphate. J Mol Biol 2007;368:1042–1050. [PubMed: 17376479]Previous structural studies by this lab demonstrated that phosphoprotein HPr binds to CcpA outside of the canonical effector binding site of the regulatory domain. Here, the structural means by which glucose-6-phosphate and fructose-1,6-diphosphate further enhance DNA binding is shown. The small molecules bind in the

effector site and appear to "buttress" the DNA-binding conformation, bolstering interactions between CcpA and phosphorylated HPr

- 9. Saier MH Jr. Cyclic AMP-independent catabolite repression in bacteria. FEMS Microbiol Lett 1996;138:97–103. [PubMed: 9026456]
- 10. Shimada T, Fujita N, Maeda M, Ishihama A. Systematic search for the Cra-binding promoters using genomic SELEX system. Genes Cells 2005;10:907–918. [PubMed: 16115199]
- 11. Choi KY, Lu F, Zalkin H. Mutagenesis of amino acid residues required for binding of corepressors to the purine repressor. J Biol Chem 1994;269:24066–24072. [PubMed: 7929058]
- 12. Mironov AA, Koonin EV, Roytberg MA, Gelfand MS. Computer analysis of transcription regulatory patterns in completely sequenced bacterial genomes. Nucl Acids Res 1999;27:2981–2989. [PubMed: 10390542]
- 13. Matthews KS, Nichols JC. Lactose repressor protein: Functional properties and structure. Prog Nucleic Acid Res Mol Biol 1998;58:127–164. [PubMed: 9308365]
- 14. Weickert MJ, Adhya S. The galactose regulon of *Escherichia coli*. Mol Microbiol 1993;10:245–251. [PubMed: 7934815]
- 15. Choy HE, Park SW, Aki T, Parrack P, Fujita N, Ishihama A, Adhya S. Repression and activation of transcription by Gal and Lac repressors: Involvement of alpha subunit of RNA polymerase. EMBO J 1995;14:4523–4529. [PubMed: 7556095]
- 16. Fujita Y, Miwa Y, Galinier A, Deutscher J. Specific recognition of the *Bacillus subtilis gnt cis-*acting catabolite-responsive element by a protein complex formed between CcpA and seryl-phosporylated HPr. Mol Microbiol 1995;17:953–960. [PubMed: 8596444]
- 17. Meibom KL, Kallipolitis BH, Ebright RH, Valentin-Hansen P. Identification of the subunit of cAMP receptor protein (CRP) that functionally interacts with CytR in CRP-CytR-mediated transcriptional repression. J Biol Chem 2000;275:11951–11956. [PubMed: 10766824]
- 18. Choi KY, Zalkin H. Structural characterization and corepressor binding of the *Escherichia coli* purine repressor. J Bacteriol 1992;174:6207–6214. [PubMed: 1400170]
- 19. Kristensen HH, Valentin-Hansen P, Søgaard-Andersen L. CytR/cAMP-CRP nucleoprotein formation in *E. coli*: The CytR repressor binds its operator as a stable dimer in a ternary complex with cAMP-CRP. J Mol Biol 1996;260:113–119. [PubMed: 8764393]
- 20. Bell CE, Lewis M. A closer view of the conformation of the Lac repressor bound to operator. Nat Struct Biol 2000;7:209–214. [PubMed: 10700279]
- 21. Wilson CJ, Zhan H, Swint-Kruse L, Matthews KS. The lactose repressor system: Paradigms for regulation, allosteric behavior and protein folding. Cell Mol Life Sci 2007;64:3–16. [PubMed: 17103112]
- 22. Oehler S, Eismann ER, Krämer H, Müller-Hill B. The three operators of the *lac* operon cooperate in repression. EMBO J 1990;9:973–979. [PubMed: 2182324]
- 23. Chen J, Matthews KS. Deletion of lactose repressor carboxyl-terminal domain affects tetramer formation. J Biol Chem 1992;267:13843–13850. [PubMed: 1629185]
- 24•. Wong OK, Guthold M, Erie DA, Gelles J. Interconvertible Lac repressor-DNA loops revealed by single-molecule experiments. PLoS Biol 2008;6:e232. [PubMed: 18828671]Using single-molecule structural and kinetic methods, Wong *et al.* visualize small stable loops that form between the LacI tetramer and two operators. The loops form rapidly, even when operator spacings are not aligned on the same face of the DNA. Transitions between two distinct looped structures suggest a dynamic equilibrium of the tetrameric repressor protein between conformations that have different juxtapositions of its component dimers
- 25••. Choi PJ, Cai L, Frieda K, Xie XS. A stochastic single-molecule event triggers phenotype switching of a bacterial cell. Science 2008;322:442–446. [PubMed: 18927393]A fluorescently labeled product of the *lac* operon was used to visualize gene expression within single cells. At intermediate inducer concentrations, two phenotypes — induced and uninduced — are observed in a genetically identical cell population. This phenomenon is hypothesized to arise from stochastic dissociation of LacI from one operator in a looped complex, presumably the primary operator near the transcription start site. At high inducer concentrations, complete dissociation from both operators results in full induction of the operon

- 26. Elf J, Li GW, Xie XS. Probing transcription factor dynamics at the single-molecule level in a living cell. Science 2007;316:1191–1194. [PubMed: 17525339]
- 27. Swint-Kruse L, Zhan H, Matthews KS. Integrated insights from simulation, experiment, and mutational analysis yield new details of LacI function. Biochemistry 2005;44:11201–11213. [PubMed: 16101304]
- 28. Oehler S, Alberti S, Müller-Hill B. Induction of the *lac* promoter in the absence of DNA loops and the stoichiometry of induction. Nucl Acids Res 2006;34:606–612. [PubMed: 16432263]
- 29. Barkley MD, Riggs AD, Jobe A, Burgeois S. Interaction of effecting ligands with *lac* repressor and repressor-operator complex. Biochemistry 1975;14:1700–1712. [PubMed: 235964]
- 30. Friedman AM, Fischmann TO, Steitz TA. Crystal structure of *lac* repressor core tetramer and its implications for DNA looping. Science 1995;268:1721–1727. [PubMed: 7792597]
- 31. Slijper M, Bonvin AM, Boelens R, Kaptein R. Refined structure of *lac* repressor headpiece (1–56) determined by relaxation matrix calculations from 2D and 3D NOE data: Change of tertiary structure upon binding to the *lac* operator. J Mol Biol 1996;259:761–773. [PubMed: 8683581]
- 32. Lewis M, Chang G, Horton NC, Kercher MA, Pace HC, Schumacher MA, Brennan RG, Lu P. Crystal structure of the lactose operon repressor and its complexes with DNA and inducer. Science 1996;271:1247–1254. [PubMed: 8638105]
- 33. Kalodimos CG, Biris N, Bonvin AM, Levandoski MM, Guennuegues M, Boelens R, Kaptein R. Structure and flexibility adaptation in nonspecific and specific protein-DNA complexes. Science 2004;305:386–389. [PubMed: 15256668]
- 34. Flynn TC, Swint-Kruse L, Kong Y, Booth C, Matthews KS, Ma J. Allosteric transition pathways in the lactose repressor protein core domains: Asymmetric motions in a homodimer. Protein Sci 2003;12:2523–2541. [PubMed: 14573864]
- 35. Zhan H, Sun Z, Matthews KS. Functional impact of polar and acidic substitutions in the lactose repressor hydrophobic monomer•monomer interface with a buried lysine. Biochemistry. 2008in press
- 36•. Daber R, Stayrook S, Rosenberg A, Lewis M. Structural analysis of Lac repressor bound to allosteric effectors. J Mol Biol 2007;370:609–619. [PubMed: 17543986]Inducer, anti-inducer, and neutral compounds bind to LacI in the same canonical effector binding site, forming hydrogen bonds between the protein and sugar hydroxyl groups. The O6 hydroxyl of the galactoside appears key to forming a water-mediated hydrogen-bond network that engages both subdomains of the regulatory domain. The authors postulate that alterations in the hydrogen bonding network are central to the allosteric transitions of LacI
- 37. Taraban M, Zhan H, Whitten AE, Langley DB, Matthews KS, Swint-Kruse L, Trewhella J. Ligandinduced conformational changes and conformational dynamics in the solution structure of the lactose repressor protein. J Mol Biol 2008;376:466–481. [PubMed: 18164724]
- 38. Rolfes RJ, Zalkin H. Purification of the *Escherichia coli* purine regulon repressor and identification of corepressors. J Bacteriol 1990;172:5637–5642. [PubMed: 2211500]
- 39. Moraitis MI, Xu H, Matthews KS. Ion concentration and temperature dependence of DNA binding: Comparison of PurR and LacI repressor proteins. Biochemistry 2001;40:8109–8117. [PubMed: 11434780]
- 40• . Wilson CJ, Zhan H, Swint-Kruse L, Matthews KS. Ligand interactions with lactose repressor protein and the repressor-operator complex: The effects of ionization and oligomerization on binding. Biophys Chem 2007;126:94–105. [PubMed: 16860458]Isothermal titration calorimetry shows that LacI binding to inducer IPTG is driven by enthalpic forces, whereas a weaker inducer has low enthalpic contributions. Further, changes in pH and/or oligomerization (dimer *vs* tetramer) convert a neutral ligand into an anti-inducer. A wide range of energetic consequences occur when LacI binds to structurally similar ligands, indicating the sensitivity of binding processes and the range of effects that can occur
- 41. Nagadoi A, Morikawa S, Nakamura H, Enari M, Kobayashi K, Yamamoto H, Sampei G, Mizobuchi K, Schumacher MA, Brennan RG, et al. Structural comparison of the free and DNA-bound forms of the purine repressor DNA-binding domain. Structure 1995;3:1217–1224. [PubMed: 8591032]
- 42. Schumacher MA, Choi KY, Lu F, Zalkin H, Brennan RG. Mechanism of corepressor-mediated specific DNA binding by the purine repressor. Cell 1995;83:147–155. [PubMed: 7553867]

- 43. Schumacher MA, Glasfeld A, Zalkin H, Brennan RG. The X-ray structure of the PurR-guanine*purF* operator complex reveals the contributions of complementary electrostatic surfaces and a watermediated hydrogen bond to corepressor specificity and binding affinity. J Biol Chem 1997;272:22648–22653. [PubMed: 9278422]
- 44. Glasfeld A, Koehler AN, Schumacher MA, Brennan RG. The role of lysine 55 in determining the specificity of the purine repressor for its operators through minor groove interactions. J Mol Biol 1999;291:347–361. [PubMed: 10438625]
- 45. Huffman JL, Lu F, Zalkin H, Brennan RG. Role of residue 147 in the gene regulatory function of the *Escherichia coli* purine repressor. Biochemistry 2002;41:511–520. [PubMed: 11781089]
- 46. Mowbray SL, Björkman AJ. Conformational changes of ribose-binding protein and two related repressors are tailored to fit the functional need. J Mol Biol 1999;294:487–499. [PubMed: 10610774]
- 47••. Zhan H, Taraban M, Trewhella J, Swint-Kruse L. Subdividing repressor function: DNA binding affinity, selectivity, and allostery can be altered by amino acid substitution of nonconserved residues in a LacI/GalR homologue. Biochemistry 2008;47:8058–8069. [PubMed: 18616293]The LacI DNA-binding domain and linker were fused to the PurR regulatory domain. The chimeric protein, LLhP, does not discriminate between DNA sequences as well as LacI, and the linker structure is significantly more compact in the absence of DNA. Additional amino acid changes in the LLhP linker result in a range of functional effects. Thus, variation of linker residues can modulate different aspects of repressor function. Two point mutations increased the LLhP allosteric response by an order of magnitude
- 48. Sonenshein AL. Control of key metabolic intersections in *Bacillus subtilis*. Nat Rev Microbiol 2007;5:917–927. [PubMed: 17982469]
- 49. Loll B, Saenger W, Biesiadka J. Structure of full-length transcription regulator CcpA in the apo form. Biochim Biophys Acta 2007;1774:732–736. [PubMed: 17500051]
- 50. Schumacher MA, Allen GS, Diel M, Seidel G, Hillen W, Brennan RG. Structural basis for allosteric control of the transcription regulator CcpA by the phosphoprotein HPr-Ser46-P. Cell 2004;118:731– 741. [PubMed: 15369672]
- 51. Galinier A, Deutscher J, Martin-Verstraete I. Phosphorylation of either Crh or HPr mediates binding of CcpA to the *Bacillus subtilis xyn cre* and catabolite repression of the *xyn* operon. J Mol Biol 1999;286:307–314. [PubMed: 9973552]
- 52. Müller W, Horstmann N, Hillen W, Sticht H. The transcription regulator RbsR represents a novel interaction partner of the phosphoprotein HPr-Ser46-P in *Bacillus subtilis*. FEBS J 2006;273:1251– 1261. [PubMed: 16519689]
- 53. Senear DF, Perini LT, Gavigan SA. Analysis of interactions between CytR and CRP at CytR-regulated promoters. Methods Enzymol 1998;295:403–424. [PubMed: 9750230]
- 54. Pedersen H, Valentin-Hansen P. Protein-induced fit: The CRP activator protein changes sequencespecific DNA recognition by the CytR repressor, a highly flexible LacI member. EMBO J 1997;16:2108–2118. [PubMed: 9155036]
- 55. Jørgensen CI, Kallipolitis BH, Valentin-Hansen P. DNA-binding characteristics of the *Escherichia coli* CytR regulator: A relaxed spacing requirement between operator half-sites is provided by a flexible, unstructured interdomain linker. Mol Microbiol 1998;27:41–50. [PubMed: 9466254]
- 56. Pedersen H, Søgaard-Andersen L, Holst B, Valentin-Hansen P. Heterologous cooperativity in *Escherichia coli*. The CytR repressor both contacts DNA and the cAMP receptor protein when binding to the *deoP2* promoter . J Biol Chem 1991;266:17804–17808. [PubMed: 1655726]
- 57••. Tretyachenko-Ladokhina V, Cocco MJ, Senear DF. Flexibility and adaptability in binding of *E. coli* cytidine repressor to different operators suggests a role in differential gene regulation. J Mol Biol 2006;362:271–286. [PubMed: 16919681]Thermodynamic analyses of CytR binding to natural and synthetic operators demonstrate effects that correlate with the spacing between the two operator half-sites. These effects are mediated by the dynamic structure of the dimeric protein, with different limitations imposed by binding to variant operator DNA sequences. In this fashion, DNA sequencespecific effects are exerted on repression and induction of CytR
- 58. Kallipolitis BH, Nørregaard-Madsen M, Valentin-Hansen P. Protein-protein communication: Structural model of the repression complex formed by CytR and the global regulator CRP. Cell 1997;89:1101–1109. [PubMed: 9215632]

- 59•. Meinhardt S, Swint-Kruse L. Experimental identification of specificity determinants in the domain linker of a LacI/GalR protein: Bioinformatics-based predictions generate true positives and false negatives. Proteins 2008;73:941–957. [PubMed: 18536016]The LacI/GalR family is frequently used in the development of bioinformatics algorithms to predict which conserved or nonconserved residues are functionally important. However, different algorithms predict different residues. Here, predictions for the linker sequence were experimentally tested using an engineered homologue. Amino acid substitutions of 6 predicted and 3 non-predicted residues show that all contribute to repressor function. Several linker sites are implicated in allostery
- 60. Suckow J, Markiewicz P, Kleina LG, Miller J, Kisters-Woike B, Müller-Hill B. Genetic studies of the Lac repressor. XV: 4000 single amino acid substitutions and analysis of the resulting phenotypes on the basis of the protein structure. J Mol Biol 1996;261:509–523. [PubMed: 8794873]
- 61. Zhou YN, Chatterjee S, Roy S, Adhya S. The non-inducible nature of super-repressors of the *gal* operon in *Escherichia coli*. J Mol Biol 1995;253:414–425. [PubMed: 7473724]
- 62. Buttin G. Regulatory mechanisms in the biosynthesis of the enzymes of galactose metabolism in *Escherichia coli* K 12. I. The induced biosynthesis of galactokinase and the simultaneous induction of the enzymatic sequence. [in French]. J Mol Biol 1963;7:164–182. [PubMed: 14062650]
- 63. Falcon CM, Matthews KS. Engineered disulfide linking the hinge regions within lactose repressor dimer increases operator affinity, decreases sequence selectivity, and alters allostery. Biochemistry 2001;40:15650–15659. [PubMed: 11747440]
- 64. Falcon CM, Matthews KS. Operator DNA sequence variation enhances high affinity binding by hinge helix mutants of lactose repressor protein. Biochemistry 2000;39:11074–11083. [PubMed: 10998245]
- 65. Francke C, Kerkhoven R, Wels M, Siezen RJ. A generic approach to identify Transcription Factorspecific operator motifs; Inferences for LacI-family mediated regulation in *Lactobacillus plantarum* WCFS1. BMC Genomics 2008;9:145. [PubMed: 18371204]
- 66•. Sprehe M, Seidel G, Diel M, Hillen W. CcpA mutants with differential activities in *Bacillus subtilis*. J Mol Microbiol Biotechnol 2007;12:96–105. [PubMed: 17183216]When CcpA is mutated at residues that have conformations sensitive to HPrSerP binding, the regulator retains activation of the *ackA* operon but loses regulation for other operons. In contrast, CcpA variants with mutations in the canonical binding site for small molecules selectively retain regulation for a repressed operon $\frac{y}{x} - \frac{xy}{n}$. Thus, CcpA activation and repression may involve different allosteric states
- 67•. Stoebel DM, Dean AM, Dykhuizen DE. The cost of expression of *Escherichia coli lac* operon proteins is in the process, not the products. Genetics 2008;178:1653–1660. [PubMed: 18245823] The cost for regulating gene expression is associated with transcription and translation of the associated genes, and not with the subsequent activities of the translated proteins. The expression of a particular protein can be costly or beneficial depending on the environment. The results point to a single selective pressure for all regulation within *E. coli*
- 68••. Semsey S, Virnik K, Adhya S. Three-stage regulation of the amphibolic *gal* operon: From repressosome to GalR-free DNA. J Mol Biol 2006;358:355–363. [PubMed: 16524589]GalR binds to two operator DNA sites, creating a looped structure that is stabilized by binding of the HU protein and DNA supercoiling. Galactose binding to GalR promotes sequential disruption of the complex and generates different regulatory states for the *gal* operon

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Swint-Kruse and Matthews Page 11

Lacl/GalR Inducible System

Fig. 1.

Summary of LacI/GalR protein cycles for inducible and repressible systems. For inducible systems (upper panel), the oligomer binds to its target operator DNA, inhibiting RNA polymerase transcription in the absence of a small molecule effector. This ligand (red) is often a substrate for downstream genes or a metabolic product related to those genes (*e.g.,* allolactose for LacI, galactose for GalR). In the presence of the ligand, a conformational change in the protein diminishes operator DNA binding affinity, releasing the promoter for production of mRNA. The cycle continues when effector concentration is decreased. For repressible systems (lower panel), the protein oligomer exhibits lower affinity for its target operator DNA, and transcription is unimpeded. The presence of its cognate co-repressor ligand (teal) and/or

cofactor protein (gray) elicits a conformational shift in the repressor to a form with higher affinity for its target DNA site, which in turn decreases transcription. The regulated genes for repressible systems are often biosynthetic, and extremes of DNA binding (and hence expression of downstream genes) are lower than for inducible systems.

Common Lacl/GalR Features

Fig. 2.

Common features of LacI/GalR proteins. The structure depicts that of the PurR dimer (gray ribbons) in a complex with DNA (gold wireframe at the top of the figure) and corepressor (brown spacefilling atoms) (pdb 1wet, [43]). LacI/GalR monomers contain common structural features that include a DNA binding domain with a helix-turn-helix motif, a linker between the two major domains, and a regulatory domain that encompasses regions for oligomerization and for effector binding. The small molecule effector and known cofactor protein sites are highlighted. The fold of the DNA-binding and regulatory domains are highly conserved among the family. The linkers of LacI, PurR, and CcpA contain a hinge helix and two unstructured segments. The linker makes multiple contacts, which are outlined in the text. Two DNA binding domains of a dimer are required to bind the inverted repeat sequences of the operator DNA binding sites (right panel). These operator sequences can be direct inverted repeats or contain one or two base pairs inserted between the repeats. In a few cases (*e.g.,* CytR [57••]), more widely spaced inverted repeats separate the sites.

Fig. 3.

DNA looping by LacI/GalR proteins. Formation of DNA loops significantly enhances repression. Two types of loops can occur: (i) Proteins, such as LacI, that are tetrameric (monomers are depicted as purple circles) can bind DNA at two operator sites (one per dimer) to generate highly stable loops. (ii) Dimeric proteins, such as GalR, can bind to two different operator sites, with looping between these sites mediated by protein•protein interactions that can be promoted by DNA bending proteins (*e.g.,* GalR and HU binding, [68••]) and/or by DNA supercoiling. Allosteric response of looped complexes differs at intermediate and high effector concentrations [25••,68••]. The relative positions of the promoters, operators, and downstream genes differ for various operons.

CytR regulation: Modulated protein•protein interactions

Fig. 4.

CytR regulation. CytR is a unique variation on the LacI/GalR structural theme in that the CytR*cytO* interaction is not modulated by small ligand binding (figure adapted from reference [57••]). Instead, the CytR dimer (depicted with 2 green domains per monomer) cooperatively binds DNA via interactions with the catabolite repressor protein (CRP; dimer of blue ovals). In the presence of cytidine, the CytR allosteric change appears to disallow the simultaneous contact of both *cytO* and CRP. As a result, RNA polymerase can compete for the *cytO* binding site and RNAP-CRP direct interactions are altered, allowing transcription to occur. Variations in CytR DNA-binding affinity are achieved by varying the distance between *cytO* half-sites. CytR has been postulated to access a range of conformations that contribute to differential regulation of variant operators [57••].